Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
19114 participants
Study Classification
OBSERVATIONAL
Study Start Date
2010-01-31
Study Completion Date
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants \[ASPREE Investigator Group, 2013; www.aspree.org; McNeil et al 2017\]. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)
NCT07224347
Functional Disability
Dementia
Heart Disease
+5 more
ACTIVE_NOT_RECRUITING
ASPREE Cancer Endpoints Study
NCT01968798
Cancer
UNKNOWN
PHASE4
Mechanism Based Resistance to Aspirin
NCT00948987
Aspirin Resistance
Pharmacological Aspirin Non-responsiveness
COMPLETED
PHASE1
Aspirin Treatment for Small Unruptured InTracranial Aneurysms With Ischemic cereBrovascuLar diseasE
NCT05907902
Intracranial Aneurysm
Cerebrovascular Disease
UNKNOWN
PHASE3
Aspirin Attenuates Inflammation in Human Cerebral Aneurysms
NCT01710072
The Focus of the Study is to Monitor MRI Signal Changes and Inflammatory Biomarkers With Use of Aspirin in Patients With Unruptured Cerebral Aneurysm
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ASPREE BACKGROUND:
ASPREE (ASPirin in Reducing Events in the Elderly) is a joint US/Australian research project aiming to determine whether low-dose aspirin increases healthy life-span, defined as survival free of dementia and disability. ASPREE began in 2010 and completed recruitment in 2014. It is a randomized, double-blind, placebo-controlled, primary prevention trial of daily 100 mg of aspirin in a population of healthy older people in the United States (US) and Australia with a period of treatment averaging 4.5 years. ASPREE's primary outcome is length of survival free of dementia and disability and has secondary outcomes encompassing the major health issues related to aging. The trial involving 19,114 persons aged 70 and above (65 years and above for US minorities) is distinctive for its large size, methodological rigor and high participant retention rate in both countries.
ASPREE UNIQUE ASPECTS:
1. It is the first large scale trial to incorporate dementia-free and disability-free survival as a primary outcome. This is now recognized as an appropriate goal of treatment in a primary prevention population of this age group. Within a clinical trial context disability-free survival incorporates an estimate of the overall benefits and risks of aspirin in a single outcome measure.
2. It is one of the first primary prevention trials of aspirin to include cancer incidence, metastases or mortality as a pre-specified endpoint. Recent meta-analyses \[Rothwell et al 2010, 2011, 2012\] suggests that aspirin has a significant chemopreventive effect becoming evident after a period of 4+ years of aspirin treatment, but questions remain about the magnitude of benefit, and whether it applies to treatment of all cancers and to older people.
3. It will provide information about the impact of aspirin on a range of other conditions (e.g, dementia, CVD, stroke, depression, bleeding) where aspirin has been claimed to have benefit (or risks).
The intervention phase of the trial ended in June 2017 after the NIA determined that it was highly unlikely that aspirin would show a benefit on the overall primary outcome within the planned 5-year time frame. The study is now entering a data cleaning and analysis phase and it is anticipated that the primary results were published in September 2018.
ASPREE (ASPirin in Reducing Events in the Elderly) is a joint US/Australian research project aiming to determine whether low-dose aspirin increases healthy life-span, defined as survival free of dementia and disability. ASPREE began in 2010 and completed recruitment in 2014. It is a randomized, double-blind, placebo-controlled, primary prevention trial of daily 100 mg of aspirin in a population of healthy older people in the United States (US) and Australia with a period of treatment averaging 4.5 years. ASPREE's primary outcome is length of survival free of dementia and disability and has secondary outcomes encompassing the major health issues related to aging. The trial involving 19,114 persons aged 70 and above (65 years and above for US minorities) is distinctive for its large size, methodological rigor and high participant retention rate in both countries.
ASPREE UNIQUE ASPECTS:
1. It is the first large scale trial to incorporate dementia-free and disability-free survival as a primary outcome. This is now recognized as an appropriate goal of treatment in a primary prevention population of this age group. Within a clinical trial context disability-free survival incorporates an estimate of the overall benefits and risks of aspirin in a single outcome measure.
2. It is one of the first primary prevention trials of aspirin to include cancer incidence, metastases or mortality as a pre-specified endpoint. Recent meta-analyses \[Rothwell et al 2010, 2011, 2012\] suggests that aspirin has a significant chemopreventive effect becoming evident after a period of 4+ years of aspirin treatment, but questions remain about the magnitude of benefit, and whether it applies to treatment of all cancers and to older people.
3. It will provide information about the impact of aspirin on a range of other conditions (e.g, dementia, CVD, stroke, depression, bleeding) where aspirin has been claimed to have benefit (or risks).
The intervention phase of the trial ended in June 2017 after the NIA determined that it was highly unlikely that aspirin would show a benefit on the overall primary outcome within the planned 5-year time frame. The study is now entering a data cleaning and analysis phase and it is anticipated that the primary results were published in September 2018.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Functional Disability
Dementia
Heart Disease
Stroke
Cancer
Bleeding
Depression
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspirin
100 mg enteric-coated aspirin
100 mg enteric-coated aspirin
Intervention Type
DRUG
100 mg enteric-coated aspirin, taken daily
Placebo
Placebo
Placebo
Intervention Type
DRUG
100 mg enteric-coated placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
100 mg enteric-coated aspirin
100 mg enteric-coated aspirin, taken daily
Intervention Type
DRUG
Placebo
100 mg enteric-coated placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women
* African American and Hispanic persons age 65 or older
* Any person from another ethnic minority group and Caucasian persons age 70 or older
* Willing and able to provide informed consent, and willing to accept the study requirements
* African American and Hispanic persons age 65 or older
* Any person from another ethnic minority group and Caucasian persons age 70 or older
* Willing and able to provide informed consent, and willing to accept the study requirements
Exclusion Criteria
* A history of a diagnosed cardiovascular event
* A serious intercurrent illness likely to cause death within the next 5 years, such as terminal cancer or obstructive airways disease
* A current or recurrent condition with a high risk of major bleeding, ex: cerebral aneurysm
* Anemia
* Absolute contraindication or allergy to aspirin
* Current participation in a clinical trial
* Current continuous use of aspirin or other anti-platelet drug or anticoagulant for secondary prevention. People with previous use of aspirin for primary prevention may enter the trial, provided they agree to cease existing use of aspirin and understand that they may be subsequently randomly allocated to low dose aspirin or placebo.
* A systolic blood pressure ≥180 mmHg and / or a diastolic blood pressure ≥105 mmHg
* A history of dementia
* Severe difficulty or an inability to perform any one of the 6 Katz ADLs
* Non-compliance to taking pill
* A serious intercurrent illness likely to cause death within the next 5 years, such as terminal cancer or obstructive airways disease
* A current or recurrent condition with a high risk of major bleeding, ex: cerebral aneurysm
* Anemia
* Absolute contraindication or allergy to aspirin
* Current participation in a clinical trial
* Current continuous use of aspirin or other anti-platelet drug or anticoagulant for secondary prevention. People with previous use of aspirin for primary prevention may enter the trial, provided they agree to cease existing use of aspirin and understand that they may be subsequently randomly allocated to low dose aspirin or placebo.
* A systolic blood pressure ≥180 mmHg and / or a diastolic blood pressure ≥105 mmHg
* A history of dementia
* Severe difficulty or an inability to perform any one of the 6 Katz ADLs
* Non-compliance to taking pill
Minimum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Health and Medical Research Council, Australia
OTHER
Sponsor Role
collaborator
Bayer
INDUSTRY
Sponsor Role
collaborator
Monash University
OTHER
Sponsor Role
collaborator
Berman Center for Outcomes and Clinical Research
OTHER
Sponsor Role
collaborator
National Institute on Aging (NIA)
NIH
Sponsor Role
collaborator
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Hennepin Healthcare Research Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Murray, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
Berman Center for Outcomes and Clinical Research
John McNeil, MBBS, PHD
Role: PRINCIPAL_INVESTIGATOR
Monash University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Site Status
Palo Alto Medical Foundation Research Institute
Palo Alto, California, United States
Site Status
Howard University
Washington D.C., District of Columbia, United States
Site Status
University of Florida Department of Aging and Geriatrics
Gainesville, Florida, United States
Site Status
Morehouse School of Medicine
Atlanta, Georgia, United States
Site Status
Emory/ Atlanta VAMC
Atlanta, Georgia, United States
Site Status
Georgia Health Sciences University
Augusta, Georgia, United States
Site Status
Rush Alzheimer's Disease Center
Chicago, Illinois, United States
Site Status
University of Iowa
Iowa City, Iowa, United States
Site Status
Kansas University Medical Center
Kansas City, Kansas, United States
Site Status
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Site Status
Mary Bird Perkins Our Lady of the Lake Cancer Center
Baton Rouge, Louisiana, United States
Site Status
LSU Health Sciences- New Orleans
New Orleans, Louisiana, United States
Site Status
Tulane Medical Center
New Orleans, Louisiana, United States
Site Status
LSU Health Sciences- Shreveport
Shreveport, Louisiana, United States
Site Status
University of Michigan
Ann Arbor, Michigan, United States
Site Status
Wayne State University
Detroit, Michigan, United States
Site Status
Henry Ford Health System
Detroit, Michigan, United States
Site Status
Detroit Clinical Research Center
Novi, Michigan, United States
Site Status
HealthPartners Research Institute
Minneapolis, Minnesota, United States
Site Status
Phalen Village Clinic
Saint Paul, Minnesota, United States
Site Status
Central Jersey Medical Center
Elizabeth, New Jersey, United States
Site Status
Winthrop University Hospital
Mineola, New York, United States
Site Status
Wake Forest University Baptist Medical Center
Greensboro, North Carolina, United States
Site Status
The Brody School of Medicine at ECU
Greenville, North Carolina, United States
Site Status
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
Site Status
University of Pittsburgh Health Sciences Research Center
Pittsburgh, Pennsylvania, United States
Site Status
Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, United States
Site Status
University of Tennessee Health Science Center
Memphis, Tennessee, United States
Site Status
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Site Status
University of TX Medical Branch
Galveston, Texas, United States
Site Status
Regional Academic Health Center
Harlingen, Texas, United States
Site Status
UT Health Science Center at San Antonio
San Antonio, Texas, United States
Site Status
Clinical Trials Unit, The Canberra Hospital
Garran, Australian Capital Territory, Australia
Site Status
Illawarra Health and Medical Research Institute, University of Wollongong
Wollongong, New South Wales, Australia
Site Status
Discipline of General Practice, School of Population Health, University of Adelaide
Adelaide, South Australia, Australia
Site Status
Greater Green Triangle University
Mount Gambier, South Australia, Australia
Site Status
University of Tasmania Rural Clinical School
Burnie, Tasmania, Australia
Site Status
The Menzies Institute for Medical Research, University of Tasmania
Hobart, Tasmania, Australia
Site Status
University of Tasmania Newnham Campus
Launceston, Tasmania, Australia
Site Status
Bendigo Regional Clinical School
Bendigo, Victoria, Australia
Site Status
Geelong Hospital
Geelong, Victoria, Australia
Site Status
Monash Mildura Regional Clinical School
Mildura, Victoria, Australia
Site Status
University of Ballarat
Mount Helen, Victoria, Australia
Site Status
Monash Gippsland Regional Clinical School
Traralgon, Victoria, Australia
Site Status
The South West Alliance of Rural Health (SWARH)
Warrnambool, Victoria, Australia
Site Status
Gateway Community Health
Wodonga, Victoria, Australia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Australia
References
Explore related publications, articles, or registry entries linked to this study.
Barker AL, McNeil JJ, Seeman E, Ward SA, Sanders KM, Khosla S, Cumming RG, Pasco JA, Bohensky MA, Ebeling PR, Woods RL, Lockery JE, Wolfe R, Talevski J; ASPREE Investigator Group. A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy. Inj Prev. 2016 Aug;22(4):297-301. doi: 10.1136/injuryprev-2015-041655. Epub 2015 May 21.
Reference Type
BACKGROUND
ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013 Nov;36(2):555-64. doi: 10.1016/j.cct.2013.09.014. Epub 2013 Oct 7.
Reference Type
BACKGROUND
McQuilten ZK, Thao LTP, Bick AG, Byars S, Chan AT, Ford L, Leichter A, McNeil JJ, Murray AM, Murphy AJ, Orchard SG, Phung J, Ramshaw HS, Singh J, Tonkin AM, Umar A, Wolfe R, Wood EM, Woods RL, Lacaze P, Curtis DJ. Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. JAMA Cardiol. 2025 Oct 15. doi: 10.1001/jamacardio.2025.3756. Online ahead of print.
Reference Type
DERIVED
Thao LTP, Nguyen TL, Singh J, Byars SG, Bick AG, Ford L, Gibbs P, McNeil JJ, Murray AM, Orchard SG, Phung J, Umar A, Wood EM, Woods RL, Lacaze P, Chan AT, Curtis DJ, McQuilten ZK, Wolfe R. Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults: A Secondary Analysis of the ASPREE Randomized Clinical Trial. JAMA Oncol. 2025 Sep 25:e253593. doi: 10.1001/jamaoncol.2025.3593. Online ahead of print.
Reference Type
DERIVED
Sheets KM, Webb KL, Woods RL, Orchard SG, Beilin L, Fravel MA, Reid CM, Polkinghorne KR, Wolfe R, Zhou Z, Ryan J, Murray AM, Ernst ME. Long-Term Blood Pressure Variability and Physical Performance in Older Adults. J Clin Hypertens (Greenwich). 2025 Sep;27(9):e70139. doi: 10.1111/jch.70139.
Reference Type
DERIVED
Sultana F, Islam RM, Davis SR. Associations between declining testosterone concentrations and cognitive performance in community-dwelling older Australian women: a prospective cohort study. Climacteric. 2025 Aug 14:1-7. doi: 10.1080/13697137.2025.2539854. Online ahead of print.
Reference Type
DERIVED
Brodtmann A, Cheng N, Werden E, Neumann J, Robb C, Fitzgerald SM, Wolfe R, Tonkin AM, Orchard SG, Ryan J, Woods RL, Gao C, McNeil JJ. Cognitive trajectories and incident atrial fibrillation in the ASPREE cohort. medRxiv [Preprint]. 2025 Aug 1:2025.08.01.25332579. doi: 10.1101/2025.08.01.25332579.
Reference Type
DERIVED
Fravel MA, Ernst ME, Woods RL, Orchard SG, Ganjali S, Wetmore JB, Reid C, Ryan J, Polkinghorne KR, Wolfe R, Nelson MR, Zoungas S, Zhou Z. Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults. Circ Cardiovasc Qual Outcomes. 2025 Jun;18(6):e011719. doi: 10.1161/CIRCOUTCOMES.124.011719. Epub 2025 Apr 28.
Reference Type
DERIVED
Ward SA, Storey E, Naughton MT, Wolfe R, Hamilton GS, Law M, Kawasaki R, Abhayaratna WP, Webb KL, O'Donoghue FJ, Gasevic D, Stocks NP, Trevaks RE, Robman LD, Kolbe S, Fitzgerald SM, Orchard SG, Wong TY, McNeil JJ, Reid CM, Sinclair B, Woods RL. Obstructive sleep apnea and cerebral small vessel disease in community-based older people: an aspirin in reducing events in the elderly imaging substudy. Sleep. 2025 Feb 10;48(2):zsae204. doi: 10.1093/sleep/zsae204.
Reference Type
DERIVED
Zhou Z, Webb KL, Nelson MR, Woods RL, Ernst ME, Murray AM, Chan AT, Tonkin A, Reid CM, Orchard SG, Kirpach B, Shah RC, Stocks N, Broder JC, Wolfe R. Short- and long-term impact of aspirin cessation in older adults: a target trial emulation. BMC Med. 2024 Jul 29;22(1):306. doi: 10.1186/s12916-024-03507-8.
Reference Type
DERIVED
Wang Y, Islam RM, Hussain SM, McNeil JJ, Davis SR. Associations Between Blood Concentrations of Sex Hormones and Physical Function in Community-Dwelling Older Women: A Prospective Cohort Study. J Gerontol A Biol Sci Med Sci. 2024 Apr 1;79(4):glad287. doi: 10.1093/gerona/glad287.
Reference Type
DERIVED
Zhou Z, Tonkin AM, Curtis AJ, Murray A, Zhu C, Reid CM, Williamson JD, Ryan J, McNeil JJ, Beilin LJ, Ernst ME, Stocks N, Lacaze P, Shah RC, Woods RL, Wolfe R, Gall S, Zoungas S, Orchard SG, Nelson MR. Low-Density-Lipoprotein Cholesterol and Mortality Outcomes Among Healthy Older Adults: A Post Hoc Analysis of ASPREE Trial. J Gerontol A Biol Sci Med Sci. 2024 Apr 1;79(4):glad268. doi: 10.1093/gerona/glad268.
Reference Type
DERIVED
Fravel MA, Ernst ME, Woods RL, Beilin L, Zhou Z, Orchard SG, Chowdhury E, Reid CM, Saifuddin Ekram A, Espinoza SE, Nelson MR, Stocks N, Polkinghorne KR, Wolfe R, Ryan J. Long-term blood pressure variability and frailty risk in older adults. J Hypertens. 2024 Feb 1;42(2):244-251. doi: 10.1097/HJH.0000000000003599. Epub 2023 Nov 20.
Reference Type
DERIVED
Yu C, Bakshi A, Watts GF, Renton AE, Fulton-Howard B, Goate AM, Natarajan P, Chasman DI, Robman L, Woods RL, Guymer R, Wolfe R, Thao LTP, McNeil JJ, Tonkin AM, Nicholls SJ, Lacaze P. Genome-Wide Association Study of Cardiovascular Resilience Identifies Protective Variation in the CETP Gene. J Am Heart Assoc. 2023 Nov 7;12(21):e031459. doi: 10.1161/JAHA.123.031459. Epub 2023 Nov 6.
Reference Type
DERIVED
Salih A, Ardissino M, Wagen AZ, Bard A, Szabo L, Ryten M, Petersen SE, Altmann A, Raisi-Estabragh Z. Genome-Wide Association Study of Pericardial Fat Area in 28 161 UK Biobank Participants. J Am Heart Assoc. 2023 Nov 7;12(21):e030661. doi: 10.1161/JAHA.123.030661. Epub 2023 Oct 27.
Reference Type
DERIVED
Islam RM, Bell RJ, Berk M, Handelsman DJ, McNeil JJ, Wolfe R, Woods RL, Davis SR. Associations between low sex hormone concentrations and depression in older women: An observational study. Maturitas. 2023 Oct;176:107822. doi: 10.1016/j.maturitas.2023.107822. Epub 2023 Aug 4.
Reference Type
DERIVED
McQuilten ZK, Thao LTP, Pasricha SR, Artz AS, Bailey M, Chan AT, Cohen HJ, Lockery JE, Murray AM, Nelson MR, Schneider HG, Wolfe R, Woods RL, Wood EM, McNeil JJ. Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial. Ann Intern Med. 2023 Jul;176(7):913-921. doi: 10.7326/M23-0675. Epub 2023 Jun 20.
Reference Type
DERIVED
Lockery JE, Collyer TA, Woods RL, Orchard SG, Murray A, Nelson MR, Stocks NP, Wolfe R, Moran C, Ernst ME; ASPREE Investigator Group. Potentially inappropriate medication use is associated with increased risk of incident disability in healthy older adults. J Am Geriatr Soc. 2023 Aug;71(8):2495-2505. doi: 10.1111/jgs.18353. Epub 2023 Apr 11.
Reference Type
DERIVED
Carr PR, Webb KL, Neumann JT, Thao LTP, Beilin LJ, Ernst ME, Fitzgibbon B, Gasevic D, Nelson MR, Newman AB, Orchard SG, Owen A, Reid CM, Stocks NP, Tonkin AM, Woods RL, McNeil JJ. Associations of body size with all-cause and cause-specific mortality in healthy older adults. Sci Rep. 2023 Mar 7;13(1):3799. doi: 10.1038/s41598-023-29586-w.
Reference Type
DERIVED
Orchard SG, Lockery JE, Broder JC, Ernst ME, Espinoza S, Gibbs P, Wolfe R, Polekhina G, Zoungas S, Loomans-Kropp HA, Woods RL; ASPREE Investigator Group. Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad017. doi: 10.1093/jncics/pkad017.
Reference Type
DERIVED
Sultana F, Davis SR, Murray AM, Woods RL, McNeil JJ, Islam RM. Sex hormones, SHBG and cognitive performance among older Australian women: an observational study. Climacteric. 2023 Apr;26(2):121-128. doi: 10.1080/13697137.2023.2166824. Epub 2023 Jan 30.
Reference Type
DERIVED
Saifuddin Ekram ARM, Espinoza SE, Ernst ME, Ryan J, Beilin L, Stocks NP, Ward SA, McNeil JJ, Shah RC, Woods RL. The Association between Metabolic Syndrome, Frailty and Disability-Free Survival in Healthy Community-dwelling Older Adults. J Nutr Health Aging. 2023;27(1):1-9. doi: 10.1007/s12603-022-1860-2.
Reference Type
DERIVED
Ekram ARMS, Ryan J, Espinoza SE, Newman AB, Murray AM, Orchard SG, Fitzgerald SM, McNeil JJ, Ernst ME, Woods RL. The Association between Frailty and Dementia-Free and Physical Disability-Free Survival in Community-Dwelling Older Adults. Gerontology. 2023;69(5):549-560. doi: 10.1159/000528984. Epub 2023 Jan 7.
Reference Type
DERIVED
Zhou Z, Nelson M, Ernst ME, Reid C, McNeil J, Tonkin A; ASPREE Investigator Group. Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial. Circ Heart Fail. 2022 Jun;15(6):e009511. doi: 10.1161/CIRCHEARTFAILURE.122.009511. Epub 2022 Apr 5. No abstract available.
Reference Type
DERIVED
Yan MK, Orchard SG, Adler NR, Wolfe R, McLean C, Rodriguez LM, Woods RL, Gibbs P, Chan AT, Haydon A, Mar VJ. Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. Cancer Epidemiol. 2022 Aug;79:102173. doi: 10.1016/j.canep.2022.102173. Epub 2022 May 11.
Reference Type
DERIVED
Polkinghorne KR, Wetmore JB, Thao LTP, Wolfe R, Woods RL, Ernst ME, Nelson MR, Reid CM, Shah RC, McNeil JJ, Murray AM. Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial. Am J Kidney Dis. 2022 Dec;80(6):810-813. doi: 10.1053/j.ajkd.2022.02.019. Epub 2022 Apr 14. No abstract available.
Reference Type
DERIVED
Neumann JT, Thao LTP, Murray AM, Callander E, Carr PR, Nelson MR, Wolfe R, Woods RL, Reid CM, Shah RC, Newman AB, Williamson JD, Tonkin AM, McNeil JJ; ASPREE investigators. Prediction of disability-free survival in healthy older people. Geroscience. 2022 Jun;44(3):1641-1655. doi: 10.1007/s11357-022-00547-x. Epub 2022 Apr 14.
Reference Type
DERIVED
Islam RM, Bell RJ, Handelsman DJ, McNeil JJ, Nelson MR, Reid CM, Tonkin AM, Wolfe RS, Woods RL, Davis SR. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev. 2022 Feb;3(2):e109-e118. doi: 10.1016/S2666-7568(22)00001-0. Epub 2022 Feb 7.
Reference Type
DERIVED
Neumann JT, Riaz M, Bakshi A, Polekhina G, Thao LTP, Nelson MR, Woods RL, Abraham G, Inouye M, Reid CM, Tonkin AM, McNeil J, Lacaze P. Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older. Circ Genom Precis Med. 2022 Feb;15(1):e003429. doi: 10.1161/CIRCGEN.121.003429. Epub 2021 Dec 24.
Reference Type
DERIVED
Yan MK, Wolfe R, Orchard SG, Ernst ME, Mar VJ. Effect of methotrexate on melanoma risk in older adults: Secondary analysis of a randomised controlled trial. Australas J Dermatol. 2022 Feb;63(1):114-115. doi: 10.1111/ajd.13727. Epub 2021 Sep 28. No abstract available.
Reference Type
DERIVED
Ernst ME, Fravel MA, Webb KL, Wetmore JB, Wolfe R, Chowdhury E, Reid CM, Woods RL, Beilin L, Margolis KL, Murray AM, Polkinghorne KR. Long-Term Blood Pressure Variability and Kidney Function in Participants of the ASPREE Trial. Am J Hypertens. 2022 Feb 1;35(2):173-181. doi: 10.1093/ajh/hpab143.
Reference Type
DERIVED
Lacaze P, Riaz M, Sebra R, Hooper AJ, Pang J, Tiller J, Polekhina G, Tonkin A, Reid C, Zoungas S, Murray AM, Nicholls S, Watts G, Schadt E, McNeil JJ. Protective lipid-lowering variants in healthy older individuals without coronary heart disease. Open Heart. 2021 Jul;8(2):e001710. doi: 10.1136/openhrt-2021-001710.
Reference Type
DERIVED
Ernst ME, Ryan J, Chowdhury EK, Margolis KL, Beilin LJ, Reid CM, Nelson MR, Woods RL, Shah RC, Orchard SG, Wolfe R, Storey E, Tonkin AM, Brodtmann A, McNeil JJ, Murray AM. Long-Term Blood Pressure Variability and Risk of Cognitive Decline and Dementia Among Older Adults. J Am Heart Assoc. 2021 Jul 6;10(13):e019613. doi: 10.1161/JAHA.120.019613. Epub 2021 Jun 26.
Reference Type
DERIVED
Neumann JT, Riaz M, Bakshi A, Polekhina G, Thao LTP, Nelson MR, Woods RL, Abraham G, Inouye M, Reid CM, Tonkin AM, Williamson JD, Donnan GA, Brodtmann A, Cloud GC, McNeil JJ, Lacaze P. Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. Stroke. 2021 Aug;52(9):2882-2891. doi: 10.1161/STROKEAHA.120.033670. Epub 2021 May 27.
Reference Type
DERIVED
Lockery JE, Broder JC, Ryan J, Stewart AC, Woods RL, Chong TT, Cloud GC, Murray A, Rigby JD, Shah R, Storey E, Ward SA, Wolfe R, Reid CM, Collyer TA, Ernst ME; ASPREE Investigator Group, ASPREE Investigator Group listed on www.aspree.org. A Cohort Study of Anticholinergic Medication Burden and Incident Dementia and Stroke in Older Adults. J Gen Intern Med. 2021 Jun;36(6):1629-1637. doi: 10.1007/s11606-020-06550-2. Epub 2021 Mar 22.
Reference Type
DERIVED
Islam RM, Bell RJ, Handelsman DJ, Robinson PJ, Wolfe R, Davis SR; ASPREE Investigator Group. Longitudinal changes over three years in sex steroid hormone levels in women aged 70 years and over. Clin Endocrinol (Oxf). 2021 Mar;94(3):443-448. doi: 10.1111/cen.14401. Epub 2021 Jan 2.
Reference Type
DERIVED
Ernst ME, Chowdhury EK, Beilin LJ, Margolis KL, Nelson MR, Wolfe R, Tonkin AM, Ryan J, Woods RL, McNeil JJ, Reid CM; ASPREE Investigator Group. Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly. Hypertension. 2020 Dec;76(6):1945-1952. doi: 10.1161/HYPERTENSIONAHA.120.16209. Epub 2020 Nov 2.
Reference Type
DERIVED
Lockery JE, Ernst ME, Broder JC, Orchard SG, Murray A, Nelson MR, Stocks NP, Wolfe R, Reid CM, Liew D, Woods RL; ASPREE Investigator Group. Prescription Medication Use in Older Adults Without Major Cardiovascular Disease Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical Trial. Pharmacotherapy. 2020 Oct;40(10):1042-1053. doi: 10.1002/phar.2461.
Reference Type
DERIVED
Orchard ER, Ward PGD, Chopra S, Storey E, Egan GF, Jamadar SD. Neuroprotective Effects of Motherhood on Brain Function in Late Life: A Resting-State fMRI Study. Cereb Cortex. 2021 Jan 5;31(2):1270-1283. doi: 10.1093/cercor/bhaa293.
Reference Type
DERIVED
Mahady SE, Margolis KL, Chan A, Polekhina G, Woods RL, Wolfe R, Nelson MR, Lockery JE, Wood EM, Reid C, Ernst ME, Murray A, Thao L, McNeil JJ. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut. 2021 Apr;70(4):717-724. doi: 10.1136/gutjnl-2020-321585. Epub 2020 Aug 3.
Reference Type
DERIVED
Orchard SG, Lockery JE, Gibbs P, Polekhina G, Wolfe R, Zalcberg J, Haydon A, McNeil JJ, Nelson MR, Reid CM, Kirpach B, Murray AM, Woods RL; ASPREE Investigator Group. Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial. Contemp Clin Trials. 2020 Sep;96:106095. doi: 10.1016/j.cct.2020.106095. Epub 2020 Jul 31.
Reference Type
DERIVED
Orchard ER, Ward PGD, Sforazzini F, Storey E, Egan GF, Jamadar SD. Relationship between parenthood and cortical thickness in late adulthood. PLoS One. 2020 Jul 28;15(7):e0236031. doi: 10.1371/journal.pone.0236031. eCollection 2020.
Reference Type
DERIVED
Ward PGD, Orchard ER, Oldham S, Arnatkeviciute A, Sforazzini F, Fornito A, Storey E, Egan GF, Jamadar SD. Individual differences in haemoglobin concentration influence bold fMRI functional connectivity and its correlation with cognition. Neuroimage. 2020 Nov 1;221:117196. doi: 10.1016/j.neuroimage.2020.117196. Epub 2020 Jul 25.
Reference Type
DERIVED
Ernst ME, Chowdhury EK, Nelson MR, Reid CM, Margolis KL, Beilin L, Stocks NP, Murray AM, Wolfe R, Lockery JE, Orchard SG, Woods RL, McNeil JJ; ASPREE Investigator Group. Antihypertensive medication use and blood pressure control among treated older adults. J Clin Hypertens (Greenwich). 2020 Aug;22(8):1406-1414. doi: 10.1111/jch.13934. Epub 2020 Jul 15.
Reference Type
DERIVED
Davis SR, Martinez-Garcia A, Robinson PJ, Handelsman DJ, Desai R, Wolfe R, Bell RJ; ASPREE Investigator Group. Estrone Is a Strong Predictor of Circulating Estradiol in Women Age 70 Years and Older. J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3348-54. doi: 10.1210/clinem/dgaa429.
Reference Type
DERIVED
Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, Fitzgerald S, Lockery JE, Wolfe R, Mohebbi M, Dodd S, Murray AM, Stocks N, Fitzgerald PB, Mazza C, Agustini B, McNeil JJ. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Oct 1;77(10):1012-1020. doi: 10.1001/jamapsychiatry.2020.1214.
Reference Type
DERIVED
Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, Nelson MR, Chong TTJ, Williamson JD, Ward SA, Lockery JE, Orchard SG, Trevaks R, Kirpach B, Newman AB, Ernst ME, McNeil JJ, Shah RC; ASPREE Investigator Group. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020 Jul 21;95(3):e320-e331. doi: 10.1212/WNL.0000000000009277. Epub 2020 Mar 25.
Reference Type
DERIVED
Ryan J, Woods RL, Murray AM, Shah RC, Britt CJ, Reid CM, Wolfe R, Nelson MR, Lockery JE, Orchard SG, Trevaks RE, Chong TJ, McNeil JJ, Storey E; ASPREE Investigator Group. Normative performance of older individuals on the Hopkins Verbal Learning Test-Revised (HVLT-R) according to ethno-racial group, gender, age and education level. Clin Neuropsychol. 2021 Aug;35(6):1174-1190. doi: 10.1080/13854046.2020.1730444. Epub 2020 Feb 26.
Reference Type
DERIVED
Lockery JE, Rigby J, Collyer TA, Stewart AC, Woods RL, McNeil JJ, Reid CM, Ernst ME; ASPREE Investigator Group. Optimising medication data collection in a large-scale clinical trial. PLoS One. 2019 Dec 27;14(12):e0226868. doi: 10.1371/journal.pone.0226868. eCollection 2019.
Reference Type
DERIVED
Chowdhury EK, Nelson MR, Ernst ME, Margolis KL, Beilin LJ, Johnston CI, Woods RL, Murray AM, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Abhayaratna WP, Stocks NP, Fitzgerald SM, Orchard SG, Trevaks RE, Donnan GA, Grimm R, McNeil JJ, Reid CM; ASPREE Investigator Group. Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study. Am J Hypertens. 2020 Apr 1;33(4):350-361. doi: 10.1093/ajh/hpz192.
Reference Type
DERIVED
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM; ASPREE Investigator Group. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16.
Reference Type
DERIVED
McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group. Effect of Aspirin on Disability-free Survival in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1499-1508. doi: 10.1056/NEJMoa1800722. Epub 2018 Sep 16.
Reference Type
DERIVED
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi: 10.1056/NEJMoa1803955. Epub 2018 Sep 16.
Reference Type
DERIVED
Margolis KL, Mahady SE, Nelson MR, Ives DG, Satterfield S, Britt C, Ekram S, Lockery J, Schwartz EC, Woods RL, McNeil JJ, Wood EM. Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Contemp Clin Trials Commun. 2018 May 22;11:30-36. doi: 10.1016/j.conctc.2018.05.015. eCollection 2018 Sep.
Reference Type
DERIVED
Ryan J, Woods RL, Britt C, Murray AM, Shah RC, Reid CM, Kirpach B, Wolfe RS, Nelson MR, Lockery JE, Orchard SG, Trevaks RE, McNeil JJ, Storey E; ASPREE Investigator Group. Normative performance of healthy older individuals on the Modified Mini-Mental State (3MS) examination according to ethno-racial group, gender, age, and education level. Clin Neuropsychol. 2019 May;33(4):779-797. doi: 10.1080/13854046.2018.1488996. Epub 2018 Jul 5.
Reference Type
DERIVED
Wolfe R, Murray AM, Woods RL, Kirpach B, Gilbertson D, Shah RC, Nelson MR, Reid CM, Ernst ME, Lockery J, Donnan GA, Williamson J, McNeil JJ. The aspirin in reducing events in the elderly trial: Statistical analysis plan. Int J Stroke. 2018 Apr;13(3):335-338. doi: 10.1177/1747493017741383. Epub 2017 Nov 7.
Reference Type
DERIVED
Ward SA, Storey E, Woods RL, Hamilton GS, Kawasaki R, Janke AL, Naughton MT, O'Donoghue F, Wolfe R, Wong TY, Reid CM, Abhayaratna WP, Stocks N, Trevaks R, Fitzgerald S, Hodgson LAB, Robman L, Workman B, McNeil JJ; ASPREE Study Group. The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea- rationale and methodology of the SNORE-ASA study. Contemp Clin Trials. 2018 Jan;64:101-111. doi: 10.1016/j.cct.2017.10.016. Epub 2017 Oct 31.
Reference Type
DERIVED
Reid CM, Storey E, Wong TY, Woods R, Tonkin A, Wang JJ, Kam A, Janke A, Essex R, Abhayaratna WP, Budge MM; ASPREE Study Group. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurol. 2012 Feb 8;12:3. doi: 10.1186/1471-2377-12-3.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.aspree.org
Public ASPREE website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSR#09-3029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00501345
TERMINATED
PHASE3
Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT).
NCT03661463
UNKNOWN
PHASE2
Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting
NCT00966485
COMPLETED
NA
Duration of Platelet Inhibition by Aspirin
NCT00671021
COMPLETED
Aspirin Dose and Atherosclerosis in Patients With Heart Disease
NCT00272337
COMPLETED
PHASE4
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
NCT00748371
TERMINATED
PHASE4
Testing a Community Intervention to Increase Aspirin Use
NCT02607917
COMPLETED
NA
Aspirin Response in High Risk Patients With Coronary Artery Disease
NCT01383304
UNKNOWN
Aspirin to Target Arterial Events in Chronic Kidney Disease
NCT03796156
RECRUITING
PHASE3
PPARGC1β and CNTN4 Genotype Aspirin Study
NCT02970604
UNKNOWN
PHASE4
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
NCT00129038
COMPLETED
PHASE4
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
NCT02144831
WITHDRAWN
PHASE4
The Dual Antiplatelet Therapy Study (DAPT Study)
NCT00977938
COMPLETED
PHASE4
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
NCT01768637
COMPLETED
PHASE1
Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients
NCT04269863
UNKNOWN
NA
Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease
NCT04217447
TERMINATED
PHASE3
Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients
NCT01198379
WITHDRAWN
PHASE4
Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
NCT02550717
COMPLETED
Platelet Hyperreactivity to Aspirin and Stroke
NCT00766896
COMPLETED
PHASE4
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
NCT00501059
COMPLETED
PHASE3
Aspirin Resistance in Coronary Artery Disease
NCT00753935
COMPLETED
EARLY_PHASE1
Aortic Arch Related Cerebral Hazard Trial (ARCH)
NCT00235248
COMPLETED
PHASE3
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
NCT00727948
COMPLETED
EARLY_PHASE1
ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
NCT04912505
COMPLETED
PHASE2